Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines.
Dennis NiebelJoerg WenzelDagmar Wilsmann-TheisJana ZiobJasmin WilhelmiChristine BraegelmannPublished in: Dermatopathology (Basel, Switzerland) (2021)
(1) Background: Coronavirus disease 2019 (COVID-19) vaccines are currently employed on a population-wide scale in most countries worldwide. Data about unusual cutaneous adverse drug reactions (ADR) are scant, though. (2) Methods: We retrospectively analyzed moderate to severe vaccine-related ADR in the Department of Dermatology and Allergy of the University Hospital Bonn between May to June 2021 and analyzed related skin biopsies. (3) Results: As a specialized dermatological academic center, we encountered a total of n = 19 clinically and pathologically heterogeneous cutaneous ADR with a female predominance. Delayed cutaneous ADR occurred as late as 30 days after vaccination. The majority of ADR were mild, though a few patients required systemic treatment (antihistamines, glucocorticosteroids). (4) Conclusions: The clinico-pathological spectrum of cutaneous side effects with COVID-19 vaccines is wide; however, the benefits outweigh the risks by far. More dermatopathological studies on cutaneous ADR not limited to COVID-19 vaccines are desirable to enable a better understanding of underlying pathophysiological mechanisms.
Keyphrases
- adverse drug
- coronavirus disease
- electronic health record
- sars cov
- drug induced
- emergency department
- respiratory syndrome coronavirus
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- machine learning
- early onset
- high intensity
- data analysis
- patient reported outcomes
- medical students
- replacement therapy
- climate change
- case control